167 related articles for article (PubMed ID: 18260617)
1. 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Diaz G; Glaser KB; Guo J; Harris CM; Li J; Marcotte PA; Moskey MD; Oie T; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR
J Med Chem; 2008 Mar; 51(5):1231-41. PubMed ID: 18260617
[TBL] [Abstract][Full Text] [Related]
2. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
4. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
5. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
6. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
7. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
9. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
10. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.
Khanwelkar RR; Chen GS; Wang HC; Yu CW; Huang CH; Lee O; Chen CH; Hwang CS; Ko CH; Chou NT; Lin MW; Wang LM; Chen YC; Hseu TH; Chang CN; Hsu HC; Lin HC; Shih YC; Chou SH; Tseng HW; Liu CP; Tu CM; Hu TL; Tsai YJ; Chern JW
Bioorg Med Chem; 2010 Jul; 18(13):4674-86. PubMed ID: 20570526
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
Kim HM; Ryu DK; Choi Y; Park BW; Lee K; Han SB; Lee CW; Kang MR; Kang JS; Boovanahalli SK; Park SK; Han JW; Chun TG; Lee HY; Nam KY; Choi EH; Han G
J Med Chem; 2007 May; 50(11):2737-41. PubMed ID: 17477518
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
17. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Dai Y; Hartandi K; Ji Z; Ahmed AA; Albert DH; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Harris CM; Hickman D; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Martin RL; Olson AM; Osterling DJ; Pease LJ; Soni NB; Stewart KD; Stoll VS; Tapang P; Reuter DR; Davidsen SK; Michaelides MR
J Med Chem; 2007 Apr; 50(7):1584-97. PubMed ID: 17343372
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives.
Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL
Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
